A recent study suggests that people who come off blockbuster GLP-1 drugs like Mounjaro or Wegovy can put back on shed pounds at a significantly accelerated pace than those who halt traditional lifestyle regimens.
Findings released in a leading medical journal points out that while obese people can lose a large proportion of their body weight while undergoing treatment, the weight comes back at an estimated rate of nearly a kilo each month once they quit.
"People buying these treatments need to be cognizant of the danger of rapid rebound weight gain when the therapy ends," cautioned expert Dr. Susan Jebb.
This pace of regain means a return to original mass in about one and a half years.
Weighing Therapies
The study, which examined dozens of trials involving over 9,000 of participants, contrasted the effects of the injectable medications with other pills.
Researchers note that people who lose weight through dieting usually have a less rapid creep back—perhaps 0.1 kg a month—once they finish.
Explaining the Quick Rebound
Nutrition scientists suggest the mechanism of the jabs is key to understanding the accelerated rebound.
The injections copy a natural hormone called GLP-1, which moderates appetite.
"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production could lead to the body to produce less of its endogenous hormone, and could reduce sensitivity to its effects," said Dr. Adam Collins, a dietetics expert.
"Withdrawal of this GLP-1 'fix' results in hunger is unsuppressed, making overeating far more likely."
A Lifelong Issue?
The NHS suggest the jabs for people with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
Professionals say that, given the likelihood of relapse, the therapy should be considered ongoing.
This perspective is echoed by drug manufacturers, who note that the results "highlight the chronic nature of excess weight," comparing it to managing conditions like hypertension.
Patient Testimonies
People who have discontinued the medication describe a sudden resurgence of cravings.
"It was like a trigger activating and I was suddenly ravenous," said a patient.
This difficulty is worsened if users have not developed permanent lifestyle or habit changes during treatment.
Widespread Interest
Figures suggest that a significant number of adults in the UK have tried these injections in the last 12 months, with desire continuing to grow.
- Adoption is greater among females than males.
- The middle-aged age group shows the highest level of interest.
- A large proportion access the medications through private healthcare rather than public health services.
Finally, experts stress that while these medications are potent tools for weight loss, they are not a permanent cure and maintained weight loss hinges on combined behavioural changes.
